Special Issue

COVID-19 and Global Chronic Disease 2025: New Challenges

Message from the Guest Editors

Coronavirus disease 2019 (COVID-19) is the condition caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the COVID-19 pandemic in 2020, our perspectives on healthcare systems and research have changed. This crisis emphasized the connection between clinical practice. health policies and research. On 5 May 2023, the head of the World Health Organization declared "with great hope" an end to COVID-19 as a public health emergency. However, the end of the pandemic will not be the end of COVID-19. New SARS-CoV-2 variants are still being detected, and it is necessary to continue protecting the most vulnerable people against the disease and its complications. This Special Issue, titled "COVID-19 and Global Chronic Disease 2025: New Challenges", aims at reporting the state of the art and the new challenges resulting from COVID-19. In particular, we would like to discuss and analyze diagnostic aspects, new therapies, public health policies and social aspects related to this condition and its complications.

Guest Editors

Prof. Dr. Ludovico Abenavoli

Department of Health Sciences, University "Magna Græcia", Campus Germaneto, I-88100 Catanzaro, Italy

Dr. Filippo Lococo

Thoracic Surgery, A. Gemelli University Hospital Foundation IRCCS, I-00168 Rome, Italy

Deadline for manuscript submissions

31 December 2025



Diseases

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/234603

Diseases
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diseases@mdpi.com

mdpi.com/journal/diseases





Diseases

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed





About the Journal

Message from the Editorial Board

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, Diseases is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Maurizio Battino

Department of Odontostomatologic and Specialized Clinical Sciences, Sez-Biochimica, Faculty of Medicine, Università Politecnica delle Marche, Via Ranieri 65, 60100 Ancona, Italy

Prof. Dr. Omar Cauli

Frailty and Cognitive Impairment—FROG Research Group, University of Valencia, 46010 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.